XORTX Therapeutics Operating Income Over Time
| XRTX Stock | 0.49 0.02 3.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out XORTX Therapeutics Performance and XORTX Therapeutics Correlation. XORTX |
Cross Equities Operating Income Analysis
Compare XORTX Therapeutics and related stocks such as Appili Therapeutics, Lifeist Wellness, and Aptose Biosciences Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLI | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (7.2 M) | (6.1 M) | (16.3 M) | (24.7 M) | (7.9 M) | (2.2 M) | (190.8 K) | (171.8 K) | (180.3 K) |
| LFST | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (27.6 M) | (26.2 M) | (25.3 M) | (14.8 M) | (6.2 M) | (4.4 M) | (4.4 M) | (5.1 M) | (5.4 M) |
| APS | (3.5 M) | (5.1 M) | (4.5 M) | (5.4 M) | (11.8 K) | (11.6 M) | (13.9 M) | (11.8 M) | (29.1 M) | (26.9 M) | (55.8 M) | (65.4 M) | (42.6 M) | (52.4 M) | (26.3 M) | (23.6 M) | (24.8 M) |
| THRM | (21.6 K) | (735.4 K) | (868.8 K) | (1.1 M) | (354.5 K) | (205.5 K) | (965.3 K) | (1.2 M) | (400 K) | (607.1 K) | (8.5 M) | (5.7 M) | (3.6 M) | (1.2 M) | (1.8 M) | (1.6 M) | (1.7 M) |
XORTX Therapeutics and related stocks such as Appili Therapeutics, Lifeist Wellness, and Aptose Biosciences Operating Income description
Operating Income is the amount of profit realized from XORTX Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of XORTX Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| XORTX Therapeutics | XRTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3710 33rd Street |
| Exchange | TSX Venture Exchange |
null 0.49
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.